Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02349061 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT02349061 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 102 participants.
The verdict
NCT02349061, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of ustekinumab as measured by a reduction in disease activity for subjects with active Active Systemic Lupus Erythematosus (SLE - chronic disorder of connective tissue in which there can be skin rash, arthritis, kidney problems, and anemia, among other problems).
Interventions
- DRUG Placebo SC
- DRUG Ustekinumab IV
- DRUG Ustekinumab SC
- DRUG Placebo Infusion
- OTHER Concomitant Medication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2015-10-15 |
| Est. Completion | 2019-03-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02349061
The ClinicalTrials.gov registry entry for NCT02349061 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo SC is the first listed.
NCT02349061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02349061 about?
NCT02349061 is a clinical study titled "A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus". The purpose of this study is to evaluate the efficacy of ustekinumab as measured by a reduction in disease activity for subjects with active Active Systemic Lupus Erythematosus (SLE - chronic disorder of connective tissue in which there can be skin rash, arthritis, kidney problems, and anemia, among...
What is the current status of trial NCT02349061?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2015-10-15. Estimated completion is 2019-03-13.
What interventions are being tested in trial NCT02349061?
The interventions under investigation include: Placebo SC (DRUG), Ustekinumab IV (DRUG), Ustekinumab SC (DRUG), Placebo Infusion (DRUG), Concomitant Medication (OTHER).
Who is sponsoring clinical trial NCT02349061?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.